Moolec Science (MLECW) Non-Current Assets (2022 - 2025)
Moolec Science (MLECW) posted Non-Current Assets of $173.4 million for Q2 2025, up 693.91% sequentially from $21.8 million in Q4 2024, and down 66.12% YoY from $511.6 million in Q2 2024.
Moolec Science (MLECW) Non-Current Assets (2022 - 2025) Analysis & Trends
Moolec Science has reported Non-Current Assets for 4 years, with the latest figure at $173.4 million in Q2 2025.
- Quarterly Non-Current Assets fell 66.12% year-over-year to $173.4 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $728.2 million (up 28.2% YoY) and the FY2025 annual result came in at $173.4 million, down 66.12% from the prior year.
- Non-Current Assets climbed to $173.4 million in Q2 2025 per MLECW's latest filing, from $21.8 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $511.6 million in Q2 2024 and troughed at -$26.6 million in Q2 2023.
- A 4-year average of $70.9 million and a median of $19.3 million in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2024: Non-Current Assets slumped 676.23% in 2023, then soared 2026.92% in 2024.
- Over 4 years, Non-Current Assets stood at $12.7 million in 2022, then soared by 39.45% to $17.8 million in 2023, then rose by 22.88% to $21.8 million in 2024, then jumped by 693.91% to $173.4 million in 2025.
- According to Business Quant data, Non-Current Assets over the past three periods registered $173.4 million, $21.8 million, and $21.4 million for Q2 2025, Q4 2024, and Q3 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Moolec Science | 8,617.72 | -1.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 173.36 Mn |
| Dec 31, 2024 | 21.84 Mn |
| Sep 30, 2024 | 21.40 Mn |
| Jun 30, 2024 | 511.63 Mn |
| Mar 31, 2024 | 19.34 Mn |
| Dec 31, 2023 | 17.77 Mn |
| Sep 30, 2023 | 19.29 Mn |
| Jun 30, 2023 | -26.55 Mn |
| Mar 31, 2023 | 5.01 Mn |
| Dec 31, 2022 | 12.74 Mn |
| Jun 30, 2022 | 4.61 Mn |